Isomorphic Labs, an AI-powered drug discovery spinoff from Google DeepMind, raised $2.1B led by Thrive, after raising $600M in its first round in March 2025
Isomorphic Labs, an artificial intelligence-driven drug discovery company, said on Wednesday it has raised $2.1 billion …
Context & Ripple Effects
Isomorphic Labs has moved from its 2021 launch under Google DeepMind to drug-discovery partnerships with Eli Lilly and Novartis, then a $600M financing in March 2025. The new $2.1B round, again led by Thrive, sharply extends the capital behind that path.
The company’s arc ties DeepMind-originated AI research to pharmaceutical R&D commercialization, while its newer bioresilience work broadens the set of health applications being pursued.
First-order effects
- Isomorphic gains a substantially larger funding base to pursue AI-enabled drug discovery and advance work associated with its pharmaceutical partnerships.
- Thrive reinforces its position as the key financial backer across Isomorphic’s two reported financings, while Google DeepMind’s spinout model receives a prominent validation.
Second-order effects
- Drug-discovery AI rivals will face a higher bar for capitalization and for showing that platform capabilities can translate into valuable pharmaceutical programs and partnerships.
- Existing and prospective pharma partners gain a better-funded AI supplier, potentially increasing competition among AI platforms for access to drug-development collaborations.
Third-order effects
- If funding continues to concentrate around AI companies with frontier-model lineage and established pharma ties, drug-discovery AI may become more dominated by a small set of well-capitalized platforms rather than many lightly funded point solutions.
- The pattern shifts the central industry test from attracting AI capital to demonstrating that large AI research investments can reliably produce drug-development outcomes; the related coverage does not yet establish those outcomes.
The trend: Drug-discovery AI is evolving from research-led startups toward heavily financed platform companies built around deep AI capabilities and pharmaceutical distribution partnerships.